Lipidor submits new patent application and expands collaboration with Cannassure using Lipidor’s AKVANO[®] technology for medicinal cannabis products
Stockholm, Sweden, 29 October 2021 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) today announced that the collaboration agreement with Cannassure Therapeutics has expanded to include a new patent family covering new innovative AKVANO[®] topical compositions. Lipidor submitted the new patent application to the European Patent Office on 25 October 2021.Earlier this year, Lipidor signed an exclusive licensing agreement with Cannassure Therapeutics for the use of Lipidor’s patented drug delivery technology AKVANO[® ]in topical medical cannabis products, and the programs are